Teva Blocked Generic Inhalers for 10 Years — Now They Owe You $35M

本站添加: 2026-05-25

[00:00:00]Teva Pharmaceuticals just agreed to pay $35 million to settle an antitrust lawsuit over Qvar inhalers, a branded asthma medication that has had no generic alternative for over a decade.

[00:00:14]The lawsuit alleged that Teva listed patents in the FDA's Orange Book that did not qualify for listing and discontinued older inhaler versions so newer ones kept patent protection.

[00:00:28]That is a practice called product hopping.

[00:00:31]The result, generic competitors were blocked from the market for years and patients paid more than they needed to.

[00:00:39]If you purchased a Qvar or Qvar Redihaler inhaler between January 2015 and July 2025 in one of 42 covered states or DC, you can file a claim. The settlement website is qvarantitrustsettlement.com.

[00:00:57]The deadline to file is July 31st, 2026.

[00:01:01]As part of the settlement, Teva also agreed to delist six patents from the Orange Book, which removes one of the barriers that kept generic competitors out.

[00:01:12]You can check whether your state is covered and file your claim at the link in my description.

[00:01:18]I cover settlements like this before the deadlines pass. Subscribe so you don't miss the next one.